Table 2.
Phenotypic drug susceptibility testing results of strain H37Rv and clinical non-MDR, MDR, and XDR isolates using the MGIT 960 system
INH, isoniazid; RMP, rifampicin; EMB, ethambutol; PZA, pyrazinamide; MFX, moxifloxacin; BDQ, bedaquiline; LZD, linezolid; CFZ, clofazimine; AMK, amikacin; DLM, delamanid; PTO, protionamide. All concentrations are in μg/ml. R, resistant; S, susceptible; ND, not determined.
| Isolate | PIPD1 |
First line |
Second line |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.25 | 0.5 | 1 | 2 | INH 0.1 | RMP 1 | EMB 5 | PZA 100 | MXF 0.25 | MFX 1 | BDQ 1 | LZD 1 | CFZ 1 | AMK 1 | DLM 0.06 | PTO 2.5 | ||
| 19000579 | H37Rv | R | R | S | S | S | S | S | S | ND | ND | ND | ND | ND | ND | ND | ND |
| 19000704 | H37Rva | R | R | S | S | S | S | S | S | ND | ND | ND | ND | ND | ND | ND | ND |
| 19000772 | H37Rva | R | S | S | S | S | S | S | S | ND | ND | ND | ND | ND | ND | ND | ND |
| 19000705 | Non-MDR | R | R | S | S | S | S | S | S | ND | ND | ND | ND | ND | ND | ND | ND |
| 19000706 | Non-MDR | R | S | S | S | S | S | S | S | ND | ND | ND | ND | ND | ND | ND | ND |
| 19000707 | Non-MDR | R | S | S | S | S | S | S | S | ND | ND | ND | ND | ND | ND | ND | ND |
| 19000773 | MDR | R | R | S | S | R | R | R | R | S | S | S | S | S | S | S | S |
| 19000774 | MDR | R | S | S | S | R | R | R | R | S | S | S | S | S | S | S | R |
| 19000775 | MDR | R | S | S | S | R | R | R | R | S | S | S | S | S | S | S | R |
| 19000776 | XDR | R | R | S | S | R | R | R | R | R | R | ND | S | ND | R | ND | R |
| 19000777 | XDR | R | S | S | S | R | R | R | R | R | R | S | S | S | R | S | R |
a Replicates of H37Rv tested in parallel to non-MDR and MDR/XDR strains.